<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Chemocentryx Inc. — News on 6ix</title>
    <link>https://6ix.com/company/chemocentryx-inc</link>
    <description>Latest news and press releases for Chemocentryx Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 05 Feb 2026 21:28:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/chemocentryx-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7408651cc36e47533106c.webp</url>
      <title>Chemocentryx Inc.</title>
      <link>https://6ix.com/company/chemocentryx-inc</link>
    </image>
    <item>
      <title>Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/churchill-capital-corp-xi-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-february-9-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/churchill-capital-corp-xi-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-february-9-2026</guid>
      <pubDate>Thu, 05 Feb 2026 21:28:00 GMT</pubDate>
      <description>New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Churchill Capital Corp XI (Nasdaq: CCXIU) (the “Company”) announced today that, commencing February 9, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trad</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-presentations-at-the-2022-american-society-of-nephrology-and-american-college-of-rheumatology-annual-meetings</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-presentations-at-the-2022-american-society-of-nephrology-and-american-college-of-rheumatology-annual-meetings</guid>
      <pubDate>Mon, 17 Oct 2022 04:00:00 GMT</pubDate>
      <description>-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-upcoming-presentations-for-orally-administered-pd-l1-inhibitor-ccx559-at-the-2022-society-for-immunotherapy-of-cancer-sitc-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-upcoming-presentations-for-orally-administered-pd-l1-inhibitor-ccx559-at-the-2022-society-for-immunotherapy-of-cancer-sitc-annual-meeting</guid>
      <pubDate>Wed, 05 Oct 2022 04:00:00 GMT</pubDate>
      <description>-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical</description>
    </item>
    <item>
      <title>ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-tavneosr-avacopan-presentations-at-upcoming-medical-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-tavneosr-avacopan-presentations-at-upcoming-medical-conferences</guid>
      <pubDate>Wed, 24 Aug 2022 04:00:00 GMT</pubDate>
      <description>SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-appointment-of-jennifer-l-herron-to-board-as-independent-director</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-appointment-of-jennifer-l-herron-to-board-as-independent-director</guid>
      <pubDate>Tue, 05 Jul 2022 04:00:00 GMT</pubDate>
      <description>-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board -- SAN CARLOS, Calif., July 05, 2022</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Changes to its Board of Directors</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-changes-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-changes-to-its-board-of-directors</guid>
      <pubDate>Tue, 31 May 2022 04:00:00 GMT</pubDate>
      <description>-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board -- SAN CARLOS, Calif., May 31,</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-presentation-at-the-society-for-investigative-dermatology-meeting-highlighting-the-role-of-tunnels-in-driving-ongoing-disease-in-hidradenitis-suppurativa</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-presentation-at-the-society-for-investigative-dermatology-meeting-highlighting-the-role-of-tunnels-in-driving-ongoing-disease-in-hidradenitis-suppurativa</guid>
      <pubDate>Wed, 18 May 2022 04:00:00 GMT</pubDate>
      <description>-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa,</description>
    </item>
    <item>
      <title>ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-first-quarter-2022-financial-results-and-recent-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-first-quarter-2022-financial-results-and-recent-highlights</guid>
      <pubDate>Thu, 05 May 2022 04:00:00 GMT</pubDate>
      <description>-- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators</description>
    </item>
    <item>
      <title>ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-pharmacokinetic-and-pharmacodynamic-results-from-ongoing-phase-i-trial-of-orally-administered-pd-l1-inhibitor-ccx559-at-american-association-for-cancer-research-aacr-annual-meeting-2022</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-pharmacokinetic-and-pharmacodynamic-results-from-ongoing-phase-i-trial-of-orally-administered-pd-l1-inhibitor-ccx559-at-american-association-for-cancer-research-aacr-annual-meeting-2022</guid>
      <pubDate>Wed, 13 Apr 2022 04:00:00 GMT</pubDate>
      <description>-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD)</description>
    </item>
    <item>
      <title>ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-highlights</guid>
      <pubDate>Tue, 01 Mar 2022 05:00:00 GMT</pubDate>
      <description>-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following</description>
    </item>
    <item>
      <title>ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-eu-approval-of-tavneosr-avacopan-for-the-treatment-of-anca-associated-vasculitis</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-eu-approval-of-tavneosr-avacopan-for-the-treatment-of-anca-associated-vasculitis</guid>
      <pubDate>Wed, 19 Jan 2022 05:00:00 GMT</pubDate>
      <description>-- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS®</description>
    </item>
    <item>
      <title>ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-third-quarter-2021-financial-results-and-recent-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-third-quarter-2021-financial-results-and-recent-highlights</guid>
      <pubDate>Tue, 09 Nov 2021 05:00:00 GMT</pubDate>
      <description>-- U.S. Food &amp; Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- --</description>
    </item>
    <item>
      <title>ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-appoints-rita-i-jain-md-as-executive-vice-president-chief-medical-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-appoints-rita-i-jain-md-as-executive-vice-president-chief-medical-officer</guid>
      <pubDate>Mon, 11 Oct 2021 04:00:00 GMT</pubDate>
      <description>Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-fda-approval-of-tavneostm-avacopan-in-anca-associated-vasculitis</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-fda-approval-of-tavneostm-avacopan-in-anca-associated-vasculitis</guid>
      <pubDate>Fri, 08 Oct 2021 04:00:00 GMT</pubDate>
      <description>-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-approval-in-japan-of-tavneostm-avacopan-for-the-treatment-of-anca-associated-vasculitis</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-approval-in-japan-of-tavneostm-avacopan-for-the-treatment-of-anca-associated-vasculitis</guid>
      <pubDate>Mon, 27 Sep 2021 04:00:00 GMT</pubDate>
      <description>Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis SAN CARLOS, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE)</description>
    </item>
    <item>
      <title>ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-second-quarter-2021-financial-results-and-recent-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-second-quarter-2021-financial-results-and-recent-highlights</guid>
      <pubDate>Mon, 09 Aug 2021 04:00:00 GMT</pubDate>
      <description>-- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021-- --</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-filing-of-amendment-to-nda-submission-and-extension-of-the-pdufa-review-period-for-avacopan-in-the-treatment-of-anca-associated-vasculitis</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-filing-of-amendment-to-nda-submission-and-extension-of-the-pdufa-review-period-for-avacopan-in-the-treatment-of-anca-associated-vasculitis</guid>
      <pubDate>Tue, 06 Jul 2021 04:00:00 GMT</pubDate>
      <description>SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and</description>
    </item>
    <item>
      <title>ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-results-of-fda-advisory-committee-meeting-on-avacopan-in-anca-associated-vasculitis</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-announces-results-of-fda-advisory-committee-meeting-on-avacopan-in-anca-associated-vasculitis</guid>
      <pubDate>Thu, 06 May 2021 04:00:00 GMT</pubDate>
      <description>SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration</description>
    </item>
    <item>
      <title>ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-first-quarter-2021-financial-results-and-recent-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-reports-first-quarter-2021-financial-results-and-recent-highlights</guid>
      <pubDate>Thu, 29 Apr 2021 04:00:00 GMT</pubDate>
      <description>-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July</description>
    </item>
    <item>
      <title>ChemoCentryx to Host Virtual R&amp;D Day on April 14, 2021</title>
      <link>https://6ix.com/company/chemocentryx-inc/news/chemocentryx-to-host-virtual-randd-day-on-april-14-2021</link>
      <guid isPermaLink="true">https://6ix.com/company/chemocentryx-inc/news/chemocentryx-to-host-virtual-randd-day-on-april-14-2021</guid>
      <pubDate>Wed, 07 Apr 2021 04:00:00 GMT</pubDate>
      <description>MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&amp;D Day on</description>
    </item>
  </channel>
</rss>